News and Announcements
World Class Medical Cannabis Growing Project in Southern Africa Has Commenced Plantation.
- Published February 17, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
About Botanapharm
Botanapharm is an Australian registered company with the clear objective to establish Africa’s leading cannabis cultivation firm. The company has achieved licensing in some of the major cannabis countries with extremely favourable climate conditions for cannabis agriculture in Southern Africa which recently legalised cannabis farming for medicinal purpose. Botanapharm captivated important JV agreements with local partners in Lesotho, South Africa, Zimbabwe and taking-off major projects with agreed certifications and achieved top results and still in the process of improvement.
Botanapharm Major Breakthrough
Currently Botanapharm is in full fledge production mode in their certified farming grounds, and has finally received results of germination on their 1st major project grounds in Lesotho which was not an easy process due to delicate products and growth process. But thanks to the companies scientific resources and years of agriculture experience and research, Botanapharm is now available to create the utmost quality medicinal cannabis through the first major step of Seeds & Cuttings, which will then lead to a 70 days harvest after the sprouting of the plant and go through Cultivation, Drying & Processing to eventually big scale Distribution to all of the major countries internationally with high demands in medicinal cannabis, resulting in expediential income for the company and also investors.
|
Botanapharm Major Projects |
|||
| Lesotho | Zimbabwe | South Africa |
Lesotho |
| In 2018 in Lesotho, Botanapharm has signed a Joint Venture Agreement with Kana Health (Pty) Ltd. a company incorporated in Lesotho to grow cannabis | In 2019 in Zimbabwe, Botanapharm inked a Joint venture agreement with Carolina Wilderness. | In 2020 in South Africa, Botanapharm signed a Joint Venture Agreement with MEDIDOPE Pharmaceuticals to grow medical cannabis in Gauteng. | Also in 2020 in Lesotho, Botanapharm signed a Joint Venture Agreement Tau Tsehla Medical Cannabis Development to grow medical cannabis in their Mafeteng SEZ. |
Currently Botanapharm is undergoing a Master plan in Lesotho, which will create multiple opportunities for future talents and support a comfortable and efficient lifestyle for both present and future employees. And also supporting high quality research facilities to develop innovative ideas and solutions to improve even more towards cannabis agriculture.
Future Aspiration
Botanapharm has achieved exponential growth from cultivating farming grounds currently with 5ha of available soil and expecting potential cultivation of 90.5ha of crop. Botanapharm is expected to generate a revenue of 1.2mil in the second quarter of 2022. The company is expected to generate revenues in excess of $20m for the calendar year ended 31st December 2022. To further expand its operation, the Company is seeking to list on the Sydney Stock Exchange (SSX) to raise a minimum of $2,000,000 at an issue price of $0.10 each.
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
